| Company Name | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024(F) | 2025(F) | 2026(F) | 2027(F) | 2028(F) | 2029(F) | 2030(F) | 2023 Growth($M) | 2023 Growth(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | - | - | - | - | - | - | - | - | - | - | - | - | $13 | $166 | $306 | $475 | $652 | $913 | $1,099 | $1,375 | $1,824 | $2,460 | $3,305 | $4,004 | $4,714 | $261 | 40.0% |
| CSL Ltd | - | $362 | $372 | $406 | $423 | $481 | $601 | $694 | $754 | $811 | $840 | $921 | $1,018 | $640 | $1,071 | $1,072 | $1,221 | $1,347 | $1,408 | $1,509 | $1,599 | $1,712 | $1,801 | $1,894 | $1,993 | $126 | 10.3% |
| Boehringer Ingelheim International GmbH | - | - | - | - | - | - | - | - | $844 | $1,009 | $1,248 | $2,639 | $3,372 | $4,155 | $4,551 | $6,494 | $7,923 | $9,828 | - | - | - | - | - | - | - | $1,905 | 24.0% |
| Viatris Inc | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1,663 | $1,635 | $1,559 | - | - | - | - | - | - | - | ($76) | -4.6% |
| Eli Lilly and Co | $2,893 | $3,162 | $3,095 | $3,300 | $3,501 | $3,987 | $4,072 | $4,331 | $4,681 | $4,975 | $5,919 | $7,789 | $9,710 | $11,042 | $11,765 | $13,068 | $14,385 | $19,525 | $29,367 | $39,558 | $49,637 | $58,346 | $66,099 | $72,379 | $78,330 | $5,140 | 35.7% |
| Novo Nordisk AS | $3,783 | $4,886 | $5,778 | $6,133 | $7,250 | $8,503 | $9,604 | $10,796 | $11,622 | $12,072 | $12,556 | $13,468 | $14,196 | $14,785 | $15,905 | $18,765 | $21,654 | $30,886 | $39,177 | $47,433 | $55,514 | $61,032 | $69,674 | $78,311 | $85,883 | $9,232 | 42.6% |
| Takeda Pharmaceutical Co Ltd | $3,334 | $3,808 | $4,378 | $4,417 | $4,649 | $4,230 | $2,825 | $1,883 | $1,865 | $1,539 | $1,480 | $1,561 | $2,003 | $3,253 | $2,960 | $2,581 | $2,501 | $2,426 | $2,552 | $2,647 | $2,633 | $2,652 | $2,671 | $2,733 | $2,795 | ($75) | -3.0% |
| Amgen Inc | - | - | - | - | - | - | - | - | - | $10 | $141 | $319 | $550 | $661 | $887 | $1,117 | $1,296 | $1,635 | $2,649 | $2,795 | $2,909 | $3,323 | $4,119 | $4,967 | $6,204 | $339 | 26.2% |
| AstraZeneca Plc | $2,028 | $2,796 | $3,597 | $4,513 | $5,760 | $6,833 | $6,687 | $6,357 | $7,099 | $7,191 | $5,788 | $4,853 | $4,111 | $4,055 | $4,221 | $5,133 | $6,415 | $8,043 | $9,678 | $10,268 | $9,538 | $8,826 | $8,007 | $7,880 | $8,073 | $1,628 | 25.4% |
| Sanofi | $2,646 | $3,319 | $4,382 | $5,228 | $5,731 | $7,833 | $9,360 | $10,950 | $12,076 | $10,850 | $10,858 | $10,210 | $9,778 | $9,129 | $8,987 | $8,343 | $7,884 | $7,495 | $8,158 | $8,403 | $8,595 | $8,726 | $8,812 | $8,819 | $8,794 | ($389) | -4.9% |
| Pfizer Inc | $12,886 | $12,675 | $12,401 | $11,434 | $10,733 | $9,577 | $3,948 | $2,315 | $2,061 | $1,860 | $1,758 | $1,914 | $2,210 | $2,446 | $1,288 | $2,015 | $2,447 | $3,321 | $5,132 | $6,160 | $6,582 | $6,362 | $6,141 | $3,124 | $2,463 | $874 | 35.7% |
| Novartis AG | $725 | $673 | $688 | $744 | $827 | $677 | $910 | $1,200 | $1,224 | $1,140 | $1,193 | $1,233 | $1,284 | $1,297 | $1,199 | $1,104 | $971 | $1,047 | $1,325 | $1,640 | $2,151 | $2,651 | $3,019 | $3,340 | $3,645 | $76 | 7.8% |
| Merck & Co Inc | $43 | $754 | $1,748 | $2,580 | $7,650 | $8,997 | $10,059 | $10,134 | $10,168 | $9,791 | $9,810 | $7,990 | $7,268 | $6,518 | $6,071 | $5,288 | $4,513 | $3,366 | $3,355 | $2,441 | $1,683 | $1,222 | $1,503 | $1,853 | $2,255 | ($1,147) | -25.4% |
| BioMarin Pharmaceutical Inc | $47 | $86 | $180 | $246 | $292 | $342 | $400 | $438 | $614 | $770 | $999 | $1,153 | $1,274 | $1,468 | $1,564 | $1,527 | $1,591 | $1,606 | $1,721 | $1,695 | $1,679 | $1,798 | $1,804 | $1,881 | $1,963 | $15 | 0.9% |
| Merck KGaA | $311 | $326 | $371 | $404 | $421 | $481 | $514 | $523 | $502 | $485 | $429 | $746 | $865 | $982 | $1,029 | $1,022 | $978 | $954 | $976 | $999 | $1,020 | $1,040 | $1,059 | $1,077 | $1,096 | ($24) | -2.5% |
Top 15 pharma companies by Metabolic sales
The ranking of the top pharmaceutical companies has been compiled from GlobalData’s pharmaceutical revenue figures, which are based on sales of prescription medicines, including generics drugs. The rankings include historical data from 2006 to 2023 and forecast data for 2024 to 2030.
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology